These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 18667360)

  • 1. Amyloid-beta immunisation for Alzheimer's disease.
    Wisniewski T; Konietzko U
    Lancet Neurol; 2008 Sep; 7(9):805-11. PubMed ID: 18667360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AD vaccines: conclusions and future directions.
    Wisniewski T
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):160-6. PubMed ID: 19355935
    [No Abstract]   [Full Text] [Related]  

  • 3. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.
    Petrushina I; Ghochikyan A; Mktrichyan M; Mamikonyan G; Movsesyan N; Davtyan H; Patel A; Head E; Cribbs DH; Agadjanyan MG
    J Neurosci; 2007 Nov; 27(46):12721-31. PubMed ID: 18003852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.
    Wisniewski T; Boutajangout A
    Brain Struct Funct; 2010 Mar; 214(2-3):201-18. PubMed ID: 20012091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative Abeta immunotherapy approaches for Alzheimer's disease.
    Town T
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):114-27. PubMed ID: 19355932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-beta immunotherapy for Alzheimer's disease.
    Fu HJ; Liu B; Frost JL; Lemere CA
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):197-206. PubMed ID: 20205640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.
    Tarawneh R; Holtzman DM
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):144-59. PubMed ID: 19355934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advancements toward therapeutic vaccines against Alzheimer's disease.
    Herline K; Drummond E; Wisniewski T
    Expert Rev Vaccines; 2018 Aug; 17(8):707-721. PubMed ID: 30005578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?
    Li Y; Liu Y; Wang Z; Jiang Y
    Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.
    Ghochikyan A
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):128-43. PubMed ID: 19355933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part II.
    Cribbs DH; Agadjanyan MG
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):82-7. PubMed ID: 19355929
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunotherapy for Alzheimer's disease.
    Wisniewski T; Goñi F
    Biochem Pharmacol; 2014 Apr; 88(4):499-507. PubMed ID: 24412277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy.
    Nitsch RM; Hock C
    Neurotherapeutics; 2008 Jul; 5(3):415-20. PubMed ID: 18625453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Amyloid-beta protein vaccine therapy for alzheimer's disease].
    Hara H
    Nihon Naika Gakkai Zasshi; 2006 Jun; 95(6):1122-8. PubMed ID: 16846064
    [No Abstract]   [Full Text] [Related]  

  • 15. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
    Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
    ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins.
    Yu YZ; Wang WB; Chen A; Chang Q; Liu S; Zhao M; Wang S; Qiu WY; Pang XB; Xu Q; Sun ZW
    J Alzheimers Dis; 2014; 41(1):243-60. PubMed ID: 24625800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapeutic approaches for Alzheimer's disease: Exploring active and passive vaccine progress.
    Bhadane P; Roul K; Belemkar S; Kumar D
    Brain Res; 2024 Oct; 1840():149018. PubMed ID: 38782231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial.
    Kokjohn TA; Roher AE
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):88-97. PubMed ID: 19355930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active immunization with the peptide epitope vaccine Aβ3-10-KLH induces a Th2-polarized anti-Aβ antibody response and decreases amyloid plaques in APP/PS1 transgenic mice.
    Ding L; Meng Y; Zhang HY; Yin WC; Yan Y; Cao YP
    Neurosci Lett; 2016 Nov; 634():1-6. PubMed ID: 27693663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.
    Schenk D
    Nat Rev Neurosci; 2002 Oct; 3(10):824-8. PubMed ID: 12360327
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.